Ghassan El‐Haddad

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor, Johann S. de Bono, Kim N. et al. · New England Journal of Medicine · 2021 · 2.6K citations · Full text

Medicine, Oncology, Radiation Oncology +17

18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer.

Rakesh Kumar, Yan Xiu, Jian Q. Yu et al. · PubMed · 2004 · 217 citations

Medicine, Nuclear Medicine, Radiology +16

Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy

Kamran A. Ahmed, Jimmy J. Caudell, Ghassan El‐Haddad et al. · International Journal of Radiation Oncology*Biology*Physics · 2016 · 166 citations · Full text

Medicine, Oncology, Radiation Oncology +17

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy

Thomas A. Hope, Lisa Bodei, Jennifer A. Chan et al. · Journal of Nuclear Medicine · 2020 · 122 citations · Full text

Medicine, Nuclear Medicine, Oncology +17